R1 RCM Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de R1 RCM de 44.8% y 11.4% por año respectivamente. Se prevé que el BPA crezca en un 46.7% al año. Se espera que la rentabilidad financiera sea de 4.5% en 3 años.

Información clave

54.2%

Tasa de crecimiento de los beneficios

53.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare	17.1%
Tasa de crecimiento de los ingresos	11.2%
Rentabilidad financiera futura	3.2%
Cobertura de analistas	Good
Última actualización	20 May 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

R1 RCM Inc. (NASDAQ:RCM) Shares Could Be 40% Below Their Intrinsic Value Estimate

Jun 05

R1 RCM Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

May 06

R1 RCM (NASDAQ:RCM) Might Have The Makings Of A Multi-Bagger

Mar 17

Is R1 RCM Inc. (NASDAQ:RCM) Trading At A 42% Discount?

Jan 06

R1 RCM slides 7% on secondary stock offering by selling shareholder

Sep 08

R1 RCM's (NASDAQ:RCM) Promising Earnings May Rest On Soft Foundations

Aug 11

R1 RCM GAAP EPS of -$0.07 misses by $0.11, revenue of $391.9M in-line

Aug 03

R1 RCM: Long-Term Growth Story Intact Following Cloudmed Acquisition

Jul 19

News Flash: Analysts Just Made A Meaningful Upgrade To Their R1 RCM Inc. (NASDAQ:RCM) Forecasts

Jun 30

R1 RCM draws bullish views at Barclays on Cloudmed acquisition

Jun 29

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:RCM - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	3,210	123	408	584	10
12/31/2025	2,919	79	264	397	16
12/31/2024	2,610	-73	184	304	15
3/31/2024	2,313	-33	229	332	N/A
12/31/2023	2,254	3	238	340	N/A
9/30/2023	2,212	-35	151	251	N/A
6/30/2023	2,135	-65	68	168	N/A
3/31/2023	1,966	-91	-93	13	N/A
12/31/2022	1,806	-63	-103	-10	N/A
9/30/2022	1,672	-1	-95	-2	N/A
6/30/2022	1,556	45	-13	63	N/A
3/31/2022	1,518	91	189	242	N/A
12/31/2021	1,475	-505	205	257	N/A
9/30/2021	1,404	-495	190	230	N/A
6/30/2021	1,332	-512	108	145	N/A
3/31/2021	1,293	-526	62	107	N/A
12/31/2020	1,270	47	11	60	N/A
9/30/2020	1,256	14	61	121	N/A
6/30/2020	1,250	16	55	115	N/A
3/31/2020	1,231	3	-16	43	N/A
12/31/2019	1,186	-9	53	114	N/A
9/30/2019	1,135	-22	11	68	N/A
6/30/2019	1,084	-42	33	83	N/A
3/31/2019	997	-41	54	99	N/A
12/31/2018	869	-64	-15	18	N/A
9/30/2018	746	-99	-4	19	N/A
6/30/2018	619	-88	-3	23	N/A
3/31/2018	510	-92	11	39	N/A
12/31/2017	450	-76	N/A	21	N/A
9/30/2017	416	-28	N/A	-22	N/A
6/30/2017	418	-3	N/A	-57	N/A
3/31/2017	327	-36	N/A	-116	N/A
12/31/2016	593	65	N/A	-87	N/A
9/30/2016	555	68	N/A	-100	N/A
6/30/2016	445	17	N/A	-57	N/A
3/31/2016	458	35	N/A	-8	N/A
12/31/2015	117	-84	N/A	-24	N/A
9/30/2015	96	-107	N/A	-39	N/A
6/30/2015	171	-65	N/A	-23	N/A
3/31/2015	208	-55	N/A	-71	N/A
12/31/2014	210	-80	N/A	-77	N/A
9/30/2014	247	-56	N/A	-22	N/A
6/30/2014	174	-103	N/A	-47	N/A
3/31/2014	490	102	N/A	28	N/A
12/31/2013	505	130	N/A	54	N/A
9/30/2013	-220	0	N/A	52	N/A
6/30/2013	-16	41	N/A	51	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que RCM sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.4%).

Beneficios vs. Mercado: Se prevé que RCM sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que RCM sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (11.4% al año) de RCM crezcan más rápidamente que los del mercado US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 11.4% al año) de RCM crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de RCM sea baja dentro de 3 años (4.5%).

R1 RCM Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

R1 RCM Inc. Revises Earnings Guidance for the Year 2024

Consensus EPS estimates upgraded to US$0.0021 loss

R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2024

Price target decreased by 8.8% to US$19.53

R1 RCM Inc. Provides Revenue Guidance for the Year 2023

Price target increased by 7.8% to US$21.70

Recent updates

R1 RCM Inc. Revises Earnings Guidance for the Year 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

R1 RCM Inc., Annual General Meeting, May 22, 2024

R1 RCM Inc. to Report Q1, 2024 Results on May 08, 2024

Consensus EPS estimates upgraded to US$0.0021 loss

Voss Capital - R1 RCM Inc.: Bull Case Achievable Despite Negative Sentiment

New minor risk - Earnings quality

R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2024

New Mountain Partners V (AIV-D), L.P. and New Mountain Investments V, L.L.C., managed by New Mountain Capital, L.L.C. submits a non-binding proposal to acquire remaining 67.56906% stake in R1 RCM Inc. (NasdaqGS:RCM) from TowerBrook Investors, Ltd and others for approximately $4 billion.

Full year 2023 earnings: EPS misses analyst expectations

Coliseum Capital Issues an Open Letter to the Board of R1 RCM

R1 RCM Inc. Appoints Pamela L. Spikner as Principal Accounting Officer

R1 RCM Inc. (NasdaqGS:RCM) completed the acquisition of Acclara Solutions, LLC from Providence St. Joseph Health for $680 million.

R1 RCM Inc. to Report Q4, 2023 Results on Feb 27, 2024

R1 RCM Inc. Appoints Clay Ashdown as Director

R1 RCM Inc. (NasdaqGS:RCM) entered into the Purchase Agreement to acquire Acclara Solutions, LLC from Providence St. Joseph Health.

R1 RCM Inc. (NasdaqGS:RCM) entered into the Purchase Agreement to acquire Acclara Solutions, LLC from Providence St. Joseph Health.

R1 RCM Receives Notice Of Filing Delinquency from Nasdaq

R1 RCM Receives Notice Of Filing Delinquency from Nasdaq

R1 RCM Inc. announced delayed 10-Q filing

Price target decreased by 8.8% to US$19.53

R1 RCM Inc. Provides Revenue Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.071 loss in 3Q 2022)

Now 26% undervalued after recent price drop

R1 RCM Inc. Announces Janie Wade Resigns from its Board of Directors

Now 20% undervalued after recent price drop

R1 RCM Inc. to Report Q3, 2023 Results on Nov 02, 2023

Calculating The Fair Value Of R1 RCM Inc. (NASDAQ:RCM)

Returns At R1 RCM (NASDAQ:RCM) Are On The Way Up

Lead Independent Director notifies of intention to sell stock

Price target increased by 7.8% to US$21.70

R1 RCM Inc. Provides Earnings Guidance for the Year of 2023

Second quarter 2023 earnings released: EPS: US$0.001 (vs US$0.069 loss in 2Q 2022)

Is Now An Opportune Moment To Examine R1 RCM Inc. (NASDAQ:RCM)?

R1 RCM Inc. to Report Q2, 2023 Results on Aug 02, 2023

Why We're Not Concerned About R1 RCM Inc.'s (NASDAQ:RCM) Share Price

Senior VP recently sold US$487k worth of stock

R1 RCM Inc. (NASDAQ:RCM) Shares Could Be 40% Below Their Intrinsic Value Estimate

President recently sold US$327k worth of stock

President notifies of intention to sell stock

R1 RCM Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

R1 RCM Inc. Provides Earnings Guidance for the Year 2023

First quarter 2023 earnings: EPS exceeds analyst expectations

R1 RCM (NASDAQ:RCM) Might Have The Makings Of A Multi-Bagger

CEO & Director recently bought US$1.0m worth of stock

Full year 2022 earnings: EPS misses analyst expectations

R1 RCM Inc. Provides Earnings Guidance for the Fiscal Year 2023

Price target increased by 7.3% to US$16.18

R1 RCM Inc. to Report Q4, 2022 Results on Feb 16, 2023

Consensus forecasts updated

R1 RCM Inc. Announces Chief Financial Officer Changes

Is R1 RCM Inc. (NASDAQ:RCM) Trading At A 42% Discount?

R1 RCM Inc. Appoints Janie Wade as a Director of the Company, Effective January 1, 2023

R1 RCM Inc. Announces Retirement of Albert Zimmerli from the Board of Directors, Effective January 1, 2023

Price target decreased to US$15.55

Price target decreased to US$27.82

R1 RCM Inc. Provides Earnings Guidance for the Year 2022

R1 RCM Inc. to Report Q3, 2022 Results on Nov 08, 2022

R1 RCM slides 7% on secondary stock offering by selling shareholder

Key Executive recently sold US$1.0m worth of stock

R1 RCM Inc. Appoints Brian Dean as Director

R1 RCM's (NASDAQ:RCM) Promising Earnings May Rest On Soft Foundations

Key Executive exercised options and sold US$1.2m worth of stock

Independent Director recently sold US$270k worth of stock

Second quarter 2022 earnings: EPS misses analyst expectations

R1 RCM Inc. Provides Revenue Guidance for the Full Year of 2022

R1 RCM GAAP EPS of -$0.07 misses by $0.11, revenue of $391.9M in-line

Consensus forecasts updated

R1 RCM Inc. to Report Q2, 2022 Results on Aug 03, 2022